Categories: News

Interface, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before January 11, 2021; click here to submit trade information

LOS ANGELES, Jan. 08, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Interface, Inc. (NASDAQ: TILE) investors that acquired shares between March 2, 2018 and September 28, 2020. Investors have until January 11, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

The investigation focuses on whether Interface issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Interface is the subject of an press release distributed by the SEC on September 28, 2020. This SEC release, titled, “Interface and Two Former Executives Charged With Accounting and Disclosure Violations,” states that “[t]he SEC’s order against Interface, Inc. . . . finds that in multiple quarters in 2015 and 2016, the company made unsupported, manual accounting adjustments that were not compliant with GAAP.” On September 29, 2020, shares of Interface dropped in intraday trading, based on this news.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 11, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising

Staff

Recent Posts

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) --…

22 minutes ago

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply…

22 minutes ago

The Ultimate Credentialing Solution for Independent Practitioners: Transform Your Practice in 2025 With CredyApp Solo

"Solo practitioners face unique challenges in managing their credentialing needs," says Olga Khabinskay, Director of…

23 minutes ago

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

In Q1 2025, the Company will discuss the plans for NDA submission under a potential…

23 minutes ago

ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical…

23 minutes ago